Cargando…
Lymphocyte-Activation Gene 3 (LAG3) Protein as a Possible Therapeutic Target for Parkinson’s Disease: Molecular Mechanisms Connecting Neuroinflammation to α-Synuclein Spreading Pathology
Parkinson’s disease (PD) is the most common neurodegenerative movement disorder without any objective biomarker available to date. Increasing evidence highlights the critical role of neuroinflammation, including T cell responses, and spreading of aggregated α-synuclein in PD progression. Lymphocyte-...
Autores principales: | , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
MDPI
2020
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7235703/ https://www.ncbi.nlm.nih.gov/pubmed/32340360 http://dx.doi.org/10.3390/biology9040086 |
_version_ | 1783536016020209664 |
---|---|
author | Angelopoulou, Efthalia Paudel, Yam Nath Villa, Chiara Shaikh, Mohd. Farooq Piperi, Christina |
author_facet | Angelopoulou, Efthalia Paudel, Yam Nath Villa, Chiara Shaikh, Mohd. Farooq Piperi, Christina |
author_sort | Angelopoulou, Efthalia |
collection | PubMed |
description | Parkinson’s disease (PD) is the most common neurodegenerative movement disorder without any objective biomarker available to date. Increasing evidence highlights the critical role of neuroinflammation, including T cell responses, and spreading of aggregated α-synuclein in PD progression. Lymphocyte-activation gene 3 (LAG3) belongs to the immunoglobulin (Ig) superfamily expressed by peripheral immune cells, microglia and neurons and plays a key role in T cell regulation. The role of LAG3 has been extensively investigated in several human cancers, whereas until recently, the role of LAG3 in the central nervous system (CNS) has been largely unknown. Accumulating evidence highlights the potential role of LAG3 in PD pathogenesis, mainly by binding to α-synuclein fibrils and affecting its endocytosis and intercellular transmission, which sheds more light on the connection between immune dysregulation and α-synuclein spreading pathology. Serum and cerebrospinal fluid (CSF) soluble LAG3 (sLAG3) levels have been demonstrated to be potentially associated with PD development and clinical phenotype, suggesting that sLAG3 could represent an emerging PD biomarker. Specific single nucleotide polymorphisms (SNPs) of the LAG3 gene have been also related to PD occurrence especially in the female population, enlightening the pathophysiological background of gender-related PD clinical differences. Given also the ongoing clinical trials investigating various LAG3-targeting strategies in human diseases, new opportunities are being developed for PD treatment research. In this review, we discuss recent preclinical and clinical evidence on the role of LAG3 in PD pathogenesis and biomarker potential, aiming to elucidate its underlying molecular mechanisms. |
format | Online Article Text |
id | pubmed-7235703 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2020 |
publisher | MDPI |
record_format | MEDLINE/PubMed |
spelling | pubmed-72357032020-05-22 Lymphocyte-Activation Gene 3 (LAG3) Protein as a Possible Therapeutic Target for Parkinson’s Disease: Molecular Mechanisms Connecting Neuroinflammation to α-Synuclein Spreading Pathology Angelopoulou, Efthalia Paudel, Yam Nath Villa, Chiara Shaikh, Mohd. Farooq Piperi, Christina Biology (Basel) Review Parkinson’s disease (PD) is the most common neurodegenerative movement disorder without any objective biomarker available to date. Increasing evidence highlights the critical role of neuroinflammation, including T cell responses, and spreading of aggregated α-synuclein in PD progression. Lymphocyte-activation gene 3 (LAG3) belongs to the immunoglobulin (Ig) superfamily expressed by peripheral immune cells, microglia and neurons and plays a key role in T cell regulation. The role of LAG3 has been extensively investigated in several human cancers, whereas until recently, the role of LAG3 in the central nervous system (CNS) has been largely unknown. Accumulating evidence highlights the potential role of LAG3 in PD pathogenesis, mainly by binding to α-synuclein fibrils and affecting its endocytosis and intercellular transmission, which sheds more light on the connection between immune dysregulation and α-synuclein spreading pathology. Serum and cerebrospinal fluid (CSF) soluble LAG3 (sLAG3) levels have been demonstrated to be potentially associated with PD development and clinical phenotype, suggesting that sLAG3 could represent an emerging PD biomarker. Specific single nucleotide polymorphisms (SNPs) of the LAG3 gene have been also related to PD occurrence especially in the female population, enlightening the pathophysiological background of gender-related PD clinical differences. Given also the ongoing clinical trials investigating various LAG3-targeting strategies in human diseases, new opportunities are being developed for PD treatment research. In this review, we discuss recent preclinical and clinical evidence on the role of LAG3 in PD pathogenesis and biomarker potential, aiming to elucidate its underlying molecular mechanisms. MDPI 2020-04-23 /pmc/articles/PMC7235703/ /pubmed/32340360 http://dx.doi.org/10.3390/biology9040086 Text en © 2020 by the authors. Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (http://creativecommons.org/licenses/by/4.0/). |
spellingShingle | Review Angelopoulou, Efthalia Paudel, Yam Nath Villa, Chiara Shaikh, Mohd. Farooq Piperi, Christina Lymphocyte-Activation Gene 3 (LAG3) Protein as a Possible Therapeutic Target for Parkinson’s Disease: Molecular Mechanisms Connecting Neuroinflammation to α-Synuclein Spreading Pathology |
title | Lymphocyte-Activation Gene 3 (LAG3) Protein as a Possible Therapeutic Target for Parkinson’s Disease: Molecular Mechanisms Connecting Neuroinflammation to α-Synuclein Spreading Pathology |
title_full | Lymphocyte-Activation Gene 3 (LAG3) Protein as a Possible Therapeutic Target for Parkinson’s Disease: Molecular Mechanisms Connecting Neuroinflammation to α-Synuclein Spreading Pathology |
title_fullStr | Lymphocyte-Activation Gene 3 (LAG3) Protein as a Possible Therapeutic Target for Parkinson’s Disease: Molecular Mechanisms Connecting Neuroinflammation to α-Synuclein Spreading Pathology |
title_full_unstemmed | Lymphocyte-Activation Gene 3 (LAG3) Protein as a Possible Therapeutic Target for Parkinson’s Disease: Molecular Mechanisms Connecting Neuroinflammation to α-Synuclein Spreading Pathology |
title_short | Lymphocyte-Activation Gene 3 (LAG3) Protein as a Possible Therapeutic Target for Parkinson’s Disease: Molecular Mechanisms Connecting Neuroinflammation to α-Synuclein Spreading Pathology |
title_sort | lymphocyte-activation gene 3 (lag3) protein as a possible therapeutic target for parkinson’s disease: molecular mechanisms connecting neuroinflammation to α-synuclein spreading pathology |
topic | Review |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7235703/ https://www.ncbi.nlm.nih.gov/pubmed/32340360 http://dx.doi.org/10.3390/biology9040086 |
work_keys_str_mv | AT angelopoulouefthalia lymphocyteactivationgene3lag3proteinasapossibletherapeutictargetforparkinsonsdiseasemolecularmechanismsconnectingneuroinflammationtoasynucleinspreadingpathology AT paudelyamnath lymphocyteactivationgene3lag3proteinasapossibletherapeutictargetforparkinsonsdiseasemolecularmechanismsconnectingneuroinflammationtoasynucleinspreadingpathology AT villachiara lymphocyteactivationgene3lag3proteinasapossibletherapeutictargetforparkinsonsdiseasemolecularmechanismsconnectingneuroinflammationtoasynucleinspreadingpathology AT shaikhmohdfarooq lymphocyteactivationgene3lag3proteinasapossibletherapeutictargetforparkinsonsdiseasemolecularmechanismsconnectingneuroinflammationtoasynucleinspreadingpathology AT piperichristina lymphocyteactivationgene3lag3proteinasapossibletherapeutictargetforparkinsonsdiseasemolecularmechanismsconnectingneuroinflammationtoasynucleinspreadingpathology |